{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:33:58Z","timestamp":1786649638386,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy of alfuzosin, mirabegron, and their combination in terms of stone-free rates, residual fragments, stent-related pain, and lower urinary tract symptoms (LUTS) in patients undergoing Double-J (DJ) stent placement following retrograde intrarenal surgery (RIRS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A prospective, randomized, single-center trial was conducted between February 2022 and December 2023 at Gaziantep University. A total of 103 patients who underwent RIRS for unilateral renal stones measuring 1\u20132 cm followed by DJ stenting were enrolled. Patients were randomized into four groups: Group 1 (control group, no medication), Group 2 (alfuzosin 10 mg\/day), Group 3 (mirabegron 50 mg\/day), and Group 4 (combination therapy with alfuzosin and mirabegron). Pain and LUTS were assessed 30 days postoperatively using the Visual Analog Scale (VAS) and the Overactive Bladder-Validated 8 (OAB-V8) questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean age was 43.55 \u00b1 13.93 years. No statistically significant difference was found between groups with respect to stone-free rates, residual stones, pain, or LUTS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). Group 2 (alfuzosin) had the lowest mean VAS (1.69 \u00b1 1.52) and OAB-V8 (13.5 \u00b1 7.37) scores; however, these differences were not statistically significant when compared to the control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.112 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.592, respectively). Residual stones were detected in 15.5% of patients, and stone size was identified as a significant predictor (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.025).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The use of alfuzosin and mirabegron, either alone or in combination, did not have a significant effect on stone-free rates, stent-related pain, and LUTS. Although lower pain and symptom scores were observed in the alfuzosin group, these findings should be interpreted with caution due to the lack of statistical significance. The relatively small sample size and single-center design represent important limitations of this study. Further large-scale, multicenter studies are warranted to clarify the potential role of these agents in the management of DJ stent-related symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ua.ua_91_25","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:00:25Z","timestamp":1775829625000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy of alfuzosin and mirabegron on symptoms associated with Double-J stent placement after retrograde intrarenal surgery"],"prefix":"10.4103","volume":"18","author":[{"given":"Mehmet","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[{"name":"Department of Urology, University of Gaziantep, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Taskir","sequence":"additional","affiliation":[{"name":"Department of Urology, Kilis Prof. Dr. Alaeddin Yavas\u00e7a Public Hospital, Kilis, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakip","family":"Erturhan","sequence":"additional","affiliation":[{"name":"Department of Urology, Sanko University, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Zeytun","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Gaziantep, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Bayrak","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Gaziantep, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilker","family":"Seckiner","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Gaziantep, Gaziantep, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"R1-20260415","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eururo.2012.03.052","article-title":"Prevalence of kidney stones in the United States","volume":"62","author":"Scales","year":"2012","journal-title":"Eur Urol"},{"key":"R2-20260415","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.eururo.2025.03.011","article-title":"European Association of Urology guidelines on the diagnosis and treatment of urolithiasis","volume":"88","author":"Skolarikos","year":"2025","journal-title":"Eur Urol"},{"key":"R3-20260415","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1148\/radiographics.22.5.g02se081005","article-title":"Complications of ureteral stent placement","volume":"22","author":"Dyer","year":"2002","journal-title":"Radiographics"},{"key":"R4-20260415","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/01.ju.0000049198.53424.1d","article-title":"Ureteral stent symptom questionnaire: Development and validation of a multidimensional quality of life measure","volume":"169","author":"Joshi","year":"2003","journal-title":"J Urol"},{"key":"R5-20260415","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.juro.2011.04.061","article-title":"Is there a role for \u03b1-blockers in ureteral stent related symptoms? A systematic review and meta-analysis","volume":"186","author":"Yakoubi","year":"2011","journal-title":"J Urol"},{"key":"R6-20260415","first-page":"76","article-title":"The role of mirabegron in relieving double-J stent-related discomfort: A randomized controlled clinical trial","volume":"74","author":"Galal","year":"2021","journal-title":"Cent European J Urol"},{"key":"R7-20260415","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00562315","article-title":"Comparison of fixed interval and visual analogue scales for rating chronic pain","volume":"8","author":"Joyce","year":"1975","journal-title":"Eur J Clin Pharmacol"},{"key":"R8-20260415","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/nau.23420","article-title":"Evaluating the 8-item overactive bladder questionnaire (OAB-v8) using item response theory","volume":"37","author":"Peterson","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"R9-20260415","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.39119.595081.55","article-title":"Outcomes of stenting after uncomplicated ureteroscopy: Systematic review and meta-analysis","volume":"334","author":"Nabi","year":"2007","journal-title":"BMJ"},{"key":"R10-20260415","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.ju.0000048980.33855.90","article-title":"Indwelling ureteral stents: Evaluation of symptoms, quality of life and utility","volume":"169","author":"Joshi","year":"2003","journal-title":"J Urol"},{"key":"R11-20260415","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.juro.2008.09.026","article-title":"Alfuzosin to relieve ureteral stent discomfort: A prospective, randomized, placebo controlled study","volume":"181","author":"Beddingfield","year":"2009","journal-title":"J Urol"},{"key":"R12-20260415","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/end.2007.0257","article-title":"Effect of tamsulosin in preventing ureteral stent-related morbidity: A prospective study","volume":"22","author":"Damiano","year":"2008","journal-title":"J Endourol"},{"key":"R13-20260415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12894-015-0050-5","article-title":"The beneficial effect of alpha-blockers for ureteral stent-related discomfort: Systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo","volume":"15","author":"Kwon","year":"2015","journal-title":"BMC Urol"},{"key":"R14-20260415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/luts.12405","article-title":"The efficacy and safety of mirabegron in treating ureteral stent-related symptoms: A systematic review and meta-analysis","volume":"14","author":"Li","year":"2022","journal-title":"Low Urin Tract Symptoms"},{"key":"R15-20260415","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bju.14416","article-title":"Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study","volume":"122","author":"Tae","year":"2018","journal-title":"BJU Int"},{"key":"R16-20260415","first-page":"e50502","article-title":"Tamsulosin versus mirabegron in relieving ureteric stent-related symptoms: A prospective, double-blinded, randomized controlled trial","volume":"15","author":"Javid","year":"2023","journal-title":"Cureus"},{"key":"R17-20260415","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"R18-20260415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00345-024-04799-4","article-title":"Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: A multicenter prospective randomized crossover trial","volume":"42","author":"Wada","year":"2024","journal-title":"World J Urol"},{"key":"R19-20260415","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1159\/000526607","article-title":"Comparison of mirabegron plus tamsulosin and tamsulosin monotherapy for the treatment of ureteral stent-related symptoms: A prospective randomized study","volume":"106","author":"Zhang","year":"2022","journal-title":"Urol Int"},{"key":"R20-20260415","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00240-023-01478-8","article-title":"Residual fragment size following retrograde intrarenal surgery: A critical evaluation of related variables","volume":"51","author":"Uslu","year":"2023","journal-title":"Urolithiasis"},{"key":"R21-20260415","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.euf.2022.06.014","article-title":"Best practice in \u0131nterventional management of urolithiasis: An update from the European Association of Urology guidelines panel for urolithiasis 2022","volume":"9","author":"Geraghty","year":"2023","journal-title":"Eur Urol Focus"},{"key":"R22-20260415","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12894-020-00715-1","article-title":"The effect of preoperative ureteral stenting in retrograde \u0131ntrarenal surgery: A multicenter, propensity score-matched study","volume":"20","author":"Yuk","year":"2020","journal-title":"BMC Urol"}],"container-title":["Urology Annals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ua.ua_91_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:56:24Z","timestamp":1786647384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ua.ua_91_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ua.ua_91_25","relation":{},"ISSN":["0974-7796","0974-7834"],"issn-type":[{"value":"0974-7796","type":"print"},{"value":"0974-7834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-06-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}